Targeting treatment-resistant depression

Journal of Pharmacy Practice

Volumn 24, Issue 6, 2011, Pages 520-533

  Mathys, Monica ^a   Mitchell, Brian G ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

antidepressants; augmentation; depression; treatment resistant

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; ETHYL EICOSAPENTANOATE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FOLIC ACID; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL RESEARCH; COGNITIVE THERAPY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MONOTHERAPY; PHOTOTHERAPY; PSYCHOTHERAPY; REMISSION; SEXUAL DYSFUNCTION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

EID: 84856032483     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011426972     Document Type: Article

References (119)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 ; 289: 3095-3105 (Pubitemid 37432885)
2. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989 ; 262: 914-919 (Pubitemid 19208948)
3. Herrman H, Patrick DL, Diehr P, et al. Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study: functional status, health service use and treatment of people with depressive symptoms. Psychol Med. 2002 ; 32: 889-902 (Pubitemid 34823341)
4. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000 ; 57: 375-80 (Pubitemid 30202328)
5. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global Burden of Disease Study. Lancet. 1997 ; 349: 1498-1504 (Pubitemid 27216360)
6. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 ; 62: 629-640 (Pubitemid 40973438)
7. Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR-D study: treating depression in the real world. Cleveland Clinic J Med. 2008 ; 75: 57-66
8. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010 ; 24: 131-161
9. Gaynes BN. Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. J Clin Psychiatry. 2009 ; 70 (suppl 6). 10-15
10. Papakostas GI, Peterson T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003 ; 191: 444-449 (Pubitemid 36944625)
11. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 ; 163: 28-40 (Pubitemid 43050100)
12. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1231-1242
13. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 ; 354: 1243-1252
14. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as secondstep treatments: a STAR*D report. Am J Psychiatry. 2007 ; 164: 739-752 (Pubitemid 46808529)
15. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1161-1172 (Pubitemid 44464443)
16. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1519-1530 (Pubitemid 44465751)
17. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1531-1541 (Pubitemid 44465752)
18. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 ; 40: 41-50
19. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 ; 163: 1905-1917 (Pubitemid 44807782)
20. Souery D, Papakostas GI, Trivedi MH. Treatment resistant depression. J Clin Psychiatry. 2006 ; 67 (suppl 6). 16-22
21. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007 ; 68: 1062-1070 (Pubitemid 47340327)
22. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 ; 37: 518-522 (Pubitemid 26367218)
23. Stek ML, Van Exel E, Van Tilburg W, et al. The prognosis of depression in old age: outcome six to eight years after clinical treatment. Aging Ment Health. 2002 ; 6: 282-285 (Pubitemid 34966665)
24. Iosifescu DV, Nierenberg AA, Alpert JE, et al. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003 ; 160: 2122-2127 (Pubitemid 39619604)
25. Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008 ; 69: 246-258 (Pubitemid 351469268)
26. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006 ; 31: 1841-1853
27. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998 ; 50: 97-108 (Pubitemid 28551779)
28. Van Londen L, Molenaar RPG, Goekoop JG, et al. Three to 5 year prospective follow-up of outcome in major depression. Psychol Med. 1998 ; 28: 731-735 (Pubitemid 28241305)
29. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003 ; 53: 649-659 (Pubitemid 39658481)
30. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997 ; 58 (suppl 13). 23-29 (Pubitemid 28011969)
31. Fekadu A, Wooderson S, Donaldson D, et al. A multidimentional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009 ; 70: 177-184
32. Texas Implementation of Medication Algorithms. Major depressive disorder algorithms. www.dshs.state.tx.us/mhprograms/tima.shtml. Accessed 10/22/2009
33. American Psychiatric Association Practice Guidelines. Treatment of patients with major depressive disorder, 3rd ed. www.psychiatryonline.com/ pracGuide/pracGuideTopic-7.aspx. Accessed 3/28/2011.
34. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry. 1999 ; 175: 12-16 (Pubitemid 29307849)
35. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000 ; 20: 483-487 (Pubitemid 30463766)
36. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002 ; 24: 1194-1200 (Pubitemid 34833240)
37. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002 ; 26: 1129-1134 (Pubitemid 35256105)
38. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005 ; 22: 68-76
39. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002 ; 59: 233-239 (Pubitemid 34212500)
40. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 ; 62: 413-420 (Pubitemid 32717873)
41. Fava M, Papakostas GI, Peterson T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 ; 15: 17-22 (Pubitemid 36723637)
42. Nierenberg AA, Papakostas GI, Peterson T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 ; 64: 35-39 (Pubitemid 36182227)
43. Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006 ; 67: 1836-1855 (Pubitemid 46055194)
44. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next step" practices. J Clin Psychiatry. 2000 ; 61: 403-408 (Pubitemid 30452205)
45. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006 ; 59: 203-210 (Pubitemid 43208965)
46. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J Clin Psychopharmacol. 2003 ; 23: 27-30 (Pubitemid 36164422)
47. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004 ; 65: 337-340
48. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002 ; 51: 183-188 (Pubitemid 34127908)
49. Hannan N, Hamzah Z, Akinpeloye HO, et al. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol. 2007 ; 21: 161-164 (Pubitemid 46280465)
50. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989 ; 50: 447-449 (Pubitemid 20024293)
51. Levitt AJ, Russell TJ, Kamil R, et al. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?. J Clin Psychiatry. 1999 ; 60: 613-616 (Pubitemid 29451558)
52. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004 ; 55: 296-300 (Pubitemid 38117167)
53. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005 ; 66 (suppl 8). 30-40 (Pubitemid 43004173)
54. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 ; 68: 826-831 (Pubitemid 47015480)
55. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009 ; 70: 387-396
56. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008 ; 69: 1228-1236
57. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder. Ann Intern Med. 2007 ; 147: 593-602 (Pubitemid 351664478)
58. Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008 ; 16: 21-30
59. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010 ; 127: 19-30
60. Shelton RC, Tellefson CG, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 ; 158: 131-134 (Pubitemid 32047260)
61. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006 ; 23: 364-372 (Pubitemid 44619788)
62. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007 ; 68: 224-236 (Pubitemid 46362643)
63. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 ; 68: 843-853 (Pubitemid 47015482)
64. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. J Clin Psychopharmacol. 2008 ; 28: 156-165
65. Berman RM, Fava M, Thase ME. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009 ; 14: 197-206
66. Crossly NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007 ; 68: 935-940 (Pubitemid 47015495)
67. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996 ; 53: 842-848 (Pubitemid 26303624)
68. Abraham G, Miley R, Stuart LJ. T3 augmentation of SSRI resistant depression. J Affect Disord. 2006 ; 91: 211-215
69. Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord. 2007 ; 103: 253-256 (Pubitemid 47445763)
70. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression. Arch Gen Psychiatry. 2007 ; 64: 679-688
71. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety. 2006 ; 23: 485-488 (Pubitemid 44917668)
72. Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007 ; 22: 179-182 (Pubitemid 46559875)
73. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 ; 64: 403-407 (Pubitemid 36547282)
74. Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008 ; 10: 187-190 (Pubitemid 351879952)
75. Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003 ; 13: 267-271
76. Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2005 ; 72: 211-218 (Pubitemid 40139086)
77. Omega-3 fatty acid in the treatment of depression. Harv Ment Health Lett. 2001 ; 18: 4-5
78. Peet M, Horrobin DF. A dose ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002 ; 59: 913-919
79. Nemets B, Stahl Z, Belmaker RH. Addition of Omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002 ; 159: 447-479
80. Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003 ; 160: 996-998 (Pubitemid 41079588)
81. Silvers KM, Woolley CC, Hamilton FC, et al. Randomized double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins, Leukot Essent Fatty Acids. 2005 ; 72: 211-218 (Pubitemid 40139086)
82. Farah A, Shelton RC. The role of L-Methylfolate in depressive disorders. CNS Spectrums. 2009 ; 14 (suppl 2). 1-8
83. Morris DM, Trivedi MH, Rush J. Folate and unipolar depression. J Altern Compliment Med. 2008 ; 14: 277-285 (Pubitemid 351519563)
84. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008 ; 13: 216-226
85. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord. 2000 ; 60: 121-130
86. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986 ; 10: 9-13 (Pubitemid 16109820)
87. Stahl SM. L-Methylfolate: A vitamin for your monoamines. J Clin Psychiatry. 2008 ; 69: 1352-1353
88. Hunter TS. L-methylfolate in the therapeutic management of major depressive disorder. J Pharm Pract. 2008 ; 21: 278-286 (Pubitemid 352019957)
89. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990 ; 336: 392-395 (Pubitemid 20252436)
90. Papkostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for selective serotonin reuptake inhibitor-resistant major depressive disorder: results of two randomized, double-blind, parallel-sequential trials. Presented at European Congress of Psychiatry Meeting, March 13, 2011.. :
91. Papakostas GI. Evidence for S-Adenosyl-L-Methionine (SAMe) for the treatment of major depressive disorder. J Clin Psychiatry. 2009 ; 70 (suppl 5). 18-22
92. Nelson JC. S-Adenosyl Methionine (SAMe) augmentation in major depressive disorder. Am J Psychiatry. 2010 ; 167: 889-891
93. Papakostas GI, Mischoulon D, Shyu I, et al. S-Adenosyl Methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 ; 167: 942-948
94. Candy B, Jones L, Williams R, et al. Psychostimulants for depression (Review). Cochrane Library. 2009 ; 1: 1-84
95. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 ; 63: 856-864 (Pubitemid 44188478)
96. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 ; 47: 351-354 (Pubitemid 30109248)
97. aan het Rot M, Collin KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 ; 67: 139-145
98. DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006 ; 60: 1343-1349 (Pubitemid 44838535)
99. Flores HB, Kenna H, Keller J, et al. Clinical and biological effects of mifepristione treatment in psychotic depression. Neuropsychopharmacology. 2006 ; 31: 628-636 (Pubitemid 43276978)
100. Gallegher P, Young A. Mifepristone treatment for depression and psychosis: a review of the therapeutic implications. Neuropsychiatr Dis Treat. 2006 ; 2: 33-42
101. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997 ; 54: 1009-1015 (Pubitemid 27476096)
102. Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004 ; 61: 714-719 (Pubitemid 38890806)
103. Kennedy SH, Segal ZV, Cohen NL, et al. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. J Clin Psychiatry. 2003 ; 64: 439-444 (Pubitemid 36547289)
104. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006 ; 63: 1337-1344 (Pubitemid 44878518)
105. UK ECT Group: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003 ; 361: 799-808
106. McCall WV, Prudic J, Olfson M, et al. Health-related quality of life following ECT in a large community sample. J Affect Disord. 2006 ; 90: 269-274 (Pubitemid 43183537)
107. Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004 ; 20: 13-20 (Pubitemid 38488810)
108. Terman M, Terman JS, Quitkin FM, et al. Light therapy for seasonal affective disorder. A review of efficacy. Neuropsychopharmacology. 1989 ; 2: 1-22 (Pubitemid 19126155)
109. Kripke DF, Mullaney DJ, Klauber MR, et al. Controlled trial of bright light for nonseasonal major depressive disorders. Biol Psychiatry. 1992 ; 31: 119-134
110. Yamada N, Martin-Iverson MT, Daimon K, et al. Clinical and chronobiological effects of light therapy on nonseasonal affective disorders. Biol Psychiatry. 1995 ; 37: 866-873
111. Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry. 2003 ; 64: 648-653 (Pubitemid 36750141)
112. Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. J Clin Psychiatry. 1991 ; 52: 336-337
113. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000 ; 47: 276-286 (Pubitemid 30109240)
114. Corcoran CD, Thomas P, Phillips J, et al. Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study. Br J Psychiatry. 2006 ; :189: 282-283 (Pubitemid 44343477)
115. Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract. 2008 ; 14: 271-280
116. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009 ; 19: 457-465
117. Stewart JW, McGrath PJ, Deliyannides DA, et al. Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?. J Psychiatr Pract. 2009 ; 15: 337-345
118. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010 ; 167: 281-288
119. Diagnostic and Statistical Manual for Mental Disorders, 4th ed, Text Revision: DSM-IV. Washington, DC: American Psychiatric Association ; 2000 :